Halogen bonding for rational drug design and new drug discovery

Expert Opinion on Drug Discovery

Volumn 7, Issue 5, 2012, Pages 375-383

  Lu, Yunxiang ^a   Liu, Yingtao ^b   Xu, Zhijian ^b   Li, Haiying ^a   Liu, Honglai ^a   Zhu, Weiliang ^b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Binding affinity; Drug design; Halogen bonding; Inhibitors

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; BLOOD CLOTTING FACTOR 10A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 9; HALOGEN; HYDROGEN; LEWIS BASE; LIGAND; PHOSPHODIESTERASE V; PROTEIN KINASE; RNA DIRECTED DNA POLYMERASE; SILDENAFIL;

BINDING AFFINITY; CHEMICAL INTERACTION; CRYSTAL STRUCTURE; DRUG DESIGN; HALOGENATION; HYDROGEN BOND; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

CRYSTALLOGRAPHY, X-RAY; DATABASES, PROTEIN; DRUG DESIGN; ENZYME INHIBITORS; HALOGENS; HIV REVERSE TRANSCRIPTASE; HUMANS; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEINS; RECEPTORS, CELL SURFACE;

EID: 84860380236     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.678829     Document Type: Review

References (76)

1. Jeffrey GA. An Introduction to Hydrogen Bonding. Oxford Univ Press; New York: 1997
2. Meyer EA, Castellano PK, Diederich F. Interactions with aromatic rings in chemical and biological recognition. Angew Chem Int Ed 2003;42:1210-50 (Pubitemid 36410287)
3. Salonen LM, Ellermann M, Diederich F. Aromatic rings in chemical and biological recognition: Energetics and structures. Angew Chem Int Ed 2011;50:4808-42
4. Stone AJ. The Theory of Intermolecular Forces. Oxford Univ Press; New York: 1996
5. Bissantz C, Kuhn B, Stahl M. A medicinal chemist's guide to molecular interactions. J Med Chem 2010;53:5061-84
6. Frontera A, Gamez P, Mascal M, et al. Putting anion-pi interactions into perspective. Angew Chem Int Ed 2011;50:9564-83
7. Egli M, Sarkhel S. Lone pair-Aromatic interactions: To stabilize or not to stabilize. Acc Chem Res 2007;40:197-205
8. Imai YN, Inoue Y, Yamamoto Y. Propensities of polar and aromatic amino acid in noncanonical interactions: Nonbonded contacts analysis of protein-ligand complexes in crystal structures. J Med Chem 2007;50:1189-96 (Pubitemid 46496319)
9. Metrangolo P, Resnati G. Halogen Bonding: Fundamentals and Applications. Springer; Berlin: 2008
10. Metrangolo P, Neukirch H, Pilati T, et al. Halogen bonding based recognition process: A world parallel to hydrogen bonding. Acc Chem Res 2005;38:386-95 (Pubitemid 40816650)
11. Metrangolo P, Resnati G, Pilati T, et al. Engineering functional materials by halogen bonding. J Polym Sci A Polym Chem 2007;45:1-15 (Pubitemid 46119494)
12. Metrangolo P, Meyer F, Pilati T, et al. Halogen bonding in supramolecuar chemistry. Angew Chem Int Ed 2008;47:6114-27
13. Cavallo G, Metrangolo P, Pilati T, et al. Halogen bonding: A general route in anion recognition and coordination. Chem Soc Rev 2010;39:3772-84
14. Metrangolo P, Resnati G. Halogen versus hydrogen. Science 2008;321:918-19
15. Bertani R, Sgarbossa P, Venzo A, et al. Halogen bonding in metal-organic-supramolecular networks. Coord Chem Rev 2010;254:677-95
16. Metrangolo P, Carcenac Y, Lahtinen M, et al. Nonporous organic solids capable of dynamically resolving mixtures of diiodoperfluoroalkanes. Science 2009;323:1461-4
17. Legon AC. The halogen bond: An interim perspective. Phys Chem Chem Phys 2010;12:7736-47
18. Fourmigue M. Halogen bonding: Recent advances. Curr Opin Solid State Mater Sci 2009;13:36-46
19. Rissanen K. Halogen bonded supramolecular complexes and networks. CrystEngComm 2008;10:1107-13
20. Brammer L, Espallargas GM, Libri S. Combing metals with halogen bond. CrystEngComm 2008;10:1712-27
21. Voth AR, Hays FA, Ho PS. Directing macromolecular conformations through halogen bonds. Proc Natl Acad Sci USA 2007;104:6188-93 (Pubitemid 47186070)
22. Carter M, Ho PS. Assaying the energies of biological halogen bonds. Cryst Growth Des 2011;11:5087-95
23. Hernandes MZ, Cavalcanti SMT, Moreira DRM, et al. Halogen atoms in the modern medicinal chemistry: Hints for the drug design. Curr Drug Targets 2010;11:303-14
24. Kraut DA, Churchill MJ, Dawson PE, et al. Evaluating the potential for halogen bonding in the oxyanion hole of ketosteroid isomerase using unnatural amino acid mutagenesis. ACS Chem Biol 2009;4:269-73
25. Voth AR, Khuu P, Oishi K, et al. Halogen bonds as orthogonal molecular interactions to hydrogen bonds. Nat Chem 2009;1:74-9
26. Politzer P, Lane P, Concha MC, et al. An overview of halogen bonding. J Mol Model 2007;13:305-11 (Pubitemid 46189160)
27. Politzer P, Murray JS, Concha MC. Halogen bonding: The tau-hole. J Mol Model 2007;13:291-6
28. Murray JS, Lane P, Politzer P. Expansion of the tau-hole concept. J Mol Model 2009;15:723-9
29. Politzer P, Murray JS, Clark T. Halogen bonding: An electrostatically- driven highly directional noncovalent interaction. Phys Chem Chem Phys 2010;12:7748-57
30. Murray JS, Riley KE, Politer P, et al. Directional weak intermolecular interactions: Tau-hole bonding. Aust J Chem 2010;63:1598-607
31. Sarwar MG, Dragisic B, Sagoo S, et al. A tridentate halogen-bonding receptor for tight binding of halide anions. Angew Chem Int Ed 2010;49:1674-7
32. Chudzinski MG, McClary CA, Taylor MS. Anion receptors composed of hydrogen- and halogen-bond donor groups: Modulating selectivity with combinations of district noncovalent interactions. J Am Chem Soc 2010;133:10559-68
33. Jentzsch AV, Emery D, Mareda J, et al. Ditopic ion transport systems: Anion-pi interactions and halogen bonds at work. Angew Chem Int Ed 2011;50:11675-8
34. Politzer P, Murray JS, Concha MC. Halogen bonding and the design of new materials: Organic bromines, chlorides and perhaps even fluorides as donors. J Mol Model 2007;13:643-50 (Pubitemid 47023388)
35. Lu YX, Zou JW, Yu QS, et al. Ab initio investigation of halogen bonding interactions involving fluorine as an electron acceptor. Chem Phys Lett 2007;449:6-10
36. Metrangolo P, Murray JS, Pilati T, et al. The fluorine atom as a halogen bond donor, viz. a positive site. CrystEngComm 2011;13:6593-6
37. Metrangolo P, Murray JS, Pilati T, et al. Fluorine-centered halogen bonding: A factor in recognition phenomena and reactivity. Cryst Growth Des 2011;11:4238-46
38. Lu Y, Wang Y, Xu Z, et al. C-X.H contacts in biomolecular systems: How they contribute to protein-ligand binding affinity. J Phys Chem B 2009;113:12615-21
39. Paulini R, Muller K, Dieherich F. Orthogonal multipolar interactions in structural chemistry and biology. Angew Chem Int Ed 2005;44:1788-805
40. Brammer L, Bruton EA, Sherwood P. Understanding the behavior of halogens as hydrogen bond acceptors. Cryst Growth Des 2001;1:277-90 (Pubitemid 33680419)
41. Auffinger P, Hays FA, Westhof E, et al. Halogen bonds in biological molecules. Proc Natl Acad Sci USA 2004;101:16789-94 (Pubitemid 39601317)
42. Voth AR, Ho PS. The role of halogen bonding in inhibitor recognition and binding by protein kinases. Curr Top Med Chem 2007;7:1336-48 (Pubitemid 47484763)
43. Lu Y, Wang Y, Zhu W. Nonbonding interactions of organic halogens in biological systems: Implications for drug discovery and biomolecular design. Phys Chem Chem Phys 2010;12:4543-51
44. Parisini E, Metrangolo P, Pilati T. Halogen bonding in halocarbon-protein complexes: A structural survey. Chem Soc Rev 2011;40:2267-78
45. Lu Y, Shi T, Wang Y, et al. Halogen bonding - A novel interaction for rational drug design. J Med Chem 2009;52:2854-62
46. Lu Y, Li H, Zhu X, et al. How does halogen bonding behave in solution? A theoretical study using implicit solvation model. J Phys Chem A 2011;115:4467-75
47. Lu Y, Li H, Zhu X, et al. Effects of solvent on weak halogen bonds: Density functional theory calculations. Int J Quantum Chem 2012;112:1421-30
48. Dobes P, Rezac J, Fanfrlik J, et al. Semiempirical quantum mechanical method PM6-DH2X describes the geometry and energetics of CK2-inhibitor complexes involving halogen bonds well, while the empirical potential fails. J Phys Chem B 2011;115:8581-9
49. Riley KE, Hobza P. Strength and character of halogen bonds in protein-ligand complexes. Cryst Growth Des 2011;11:4272-8
50. Ibrahim MAA. Molecular mechanical study of halogen bonding in drug design. J Comput Chem 2011;32:2564-74
51. Ibrahim MAA. Performance assessment of semiempirical molecular orbital methods in describing halogen bonding: quantum mechanical and quantum mechanical/molecular mechanical-molecular dynamics study. J Chem Inf Model 2011;51:2549-59
52. Rendine S, Pieraccini S, Forni A, et al. Halogen bonding in ligand-receptor systems in the framework of classical force fields. Phys Chem Chem Phys 2011;13:19508-16
53. Benjahad A, Guillemont J, Andries K. 3-Iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2003;13:4309-12 (Pubitemid 37490809)
54. Himmel DM, Das K, Clark AD, et al. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: A new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. J Med Chem 2005;48:7582-91 (Pubitemid 41698799)
55. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912-34 (Pubitemid 35425239)
56. Cohen P. Protein kinases-The major drug targets of the twenty-first century? Nat Rev Drug Discov 2001;1:309-15
57. Bogoyevitch MA. The isoform-specific functions of the c-Jun N-Terminal Kinases (JNKs): Differences revealed by gene targeting. Bioessays 2006;28:923-34 (Pubitemid 44433755)
58. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002;23:417-25 (Pubitemid 35247771)
59. Battistutta R, Mazzorana M, Sarno S, et al. Inspecting the structure-Activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole. Chem Biol 2005;12:1211-19 (Pubitemid 41628256)
60. Battistutta R. Structural bases of protein kinase CK2 inhibitor. Cell Mol Life Sci 2009;66:1868-89
61. Baumli S, Endicott JA, Johnson LN. Halogen bonds from the basis for selective P-TEFb inhibitor by DRB. Chem Biol 2010;17:931-6
62. Fedorov O, Huber K, Eisenreich A, et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol 2011;18:67-76
63. Grant SK, Lunney EA. Kinase inhibitor that hinges on halogen bonds. Chem Biol 2011;18:3-4
64. Refetoff S. Resistance to thyroid hormone. Clin Lab Med 1993;13:563-81 (Pubitemid 23267627)
65. Valadares NF, Salum LB, Polikarpov I, et al. Role of halogen bonds in thyroid hormone receptor selectivity: Pharmacophore-based 3D-QSSR studies. J Chem Inf Model 2009;49:2606-16
66. Eriksson AE, Baase WA, Zhang XJ, et al. Response of a protein structure to cavity-creating mutations and its relation to the hydrophobic effect. Science 1992;255:178-83
67. Eriksson AE, Baase WA, Wozniak JA, et al. A cavity-containing mutant of T4 lysozyme is stabilized by buried benzene. Nature 1992;355:371-3
68. Liu L, Basse WA, Matthews BW. Halogenated benzenes bound within a non-polar cavity in T4 lysozyme provide examples of I S and I Se halogen-bonding. J Mol Biol 2009;385:595-605
69. Nazare M, Will DW, Matter H, et al. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: A study combining structure-Activity relationship and X-ray crystallography. J Med Chem 2005;48:4511-25 (Pubitemid 40993413)
70. Matter H, Will DW, Nazare M, et al. Structural requirements for factor Xa inhibitor by 3-Oxybenzamides with neutral P1 substituents: Combining X-ray Crystallography, 3D-QSAR, and tailored scoring functions. J Med Chem 2005;48:3290-312 (Pubitemid 40637203)
71. Shi Y, Sitkoff D, Zhang J, et al. Design, structural-Activity relationship, X-ray crystal structure, and energetic contributions of a critical P1 phamacophore: 3-chloroindole-7-ylbased factor Xa inhibitors. J Med Chem 2008;51:7541-51
72. Matter H, Nazare M, Gussregen S, et al. Evidence for C-Cl/C-Br pi interactions as an important contribution to protein-ligand binding affinity. Angew Chem Int Ed 2009;48:2911-16
73. Hardegger LA, Kuhn B, Spinnler B, et al. Systematic investigation of halogen bonding in protein-ligand interactions. Angew Chem Int Ed 2011;50:314-18
74. Hardegger LA, Kuhn B, Spinnler B, et al. Halogen bonding at the active sites of human cathepsin L and MEK1 kinase: Efficient interactions in different environments. ChemMedChem 2011;6:2048-54
75. Xu Z, Liu Z, Chen T, et al. Utilization of halogen bond in lead optimization: A case study of rational design of potent phosphodiesterase type 5 (PDE 5) inhibitors. J Med Chem 2011;54:5607-11
76. Kraut DA, Churchill MJ, Dawson PE, et al. Evaluating the potential for halogen bonding in the oxyanion hole of ketosteroid isomerase using unnatural amino acid mutagenesis. ACS Chem Biol 2009;4:269-73